InsiderSignal.AI

InsiderSignal.ai

MRUS - Merus N.V.

Insider Purchase by Genmab A/S (10%)

3 Months
After Trade
Before Trade

Loading data...

Trade Summary

2 months ago, Genmab A/S, serving as 10% owner at Merus N.V. (MRUS), purchased 815,444 shares at $97.00 per share, for a total transaction value of $79,098,068.00. Following this transaction, Genmab A/S now holds 72,828,509 shares of MRUS.

This purchase represents a 1.00% increase in Genmab A/S's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, December 22, 2025 and publicly disclosed via SEC Form 4 filing on Monday, December 29, 2025, 7 days after the trade was made.

Merus N.V. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Genmab A/S

Genmab A/S

10%

Genmab A/S Logo Genmab A/S is a Danish biotechnology company founded in 1999 in Copenhagen as a European spin-off from Medarex, with initial seed funding from BankInvest Biomedical under Florian Schönharting. Specializing in the creation, development, and commercialization of differentiated antibody therapeutics for cancer and other serious diseases, Genmab's mission is to transform cancer treatment and improve patient lives through innovative solutions like its DuoBody platform for bispecific antibodies. Key milestones include its 2000 IPO on the Copenhagen Stock Exchange, the 2009 U.S. approval of Arzerra (ofatumumab) for chronic lymphocytic leukemia, and the 2015 approval of Darzalex (daratumumab) for multiple myeloma, which has driven substantial revenue growth—reaching DKK 16.474 billion in 2023 and with Darzalex generating $7.98 billion globally in 2024 through partnerships like Janssen Biotech. The company outsources manufacturing and clinical trials to contract organizations, focusing on R&D from facilities in Utrecht, Netherlands. As of April 2025, Genmab is led by President and CEO Jan van de Winkel, a co-founder who previously served as Chief Scientific Officer and has authored over 300 publications in antibody technology. In late 2025, Genmab completed its acquisition of Merus N.V., purchasing over 97% of shares at $97 per share through tender offers and a back-end merger finalized in December, delisting Merus from Nasdaq and integrating its assets to bolster Genmab's oncology pipeline. This strategic move, involving multiple share purchases totaling over 1.36 million shares in mid-to-late December, positions Genmab as a global leader in antibody therapeutics with a robust portfolio of partnered and proprietary products.

View full insider profile →

Trade Price

$97.00

Quantity

815,444

Total Value

$79,098,068.00

Shares Owned

72,828,509

Trade Date

Monday, December 22, 2025

62 days ago

SEC Filing Date

Monday, December 29, 2025

Filed 7 days after trade

HEALTHCAREBIOTECHNOLOGY

About Merus N.V.

Company Overview

No company information available
View news mentioning MRUS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/2653474

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime